weersuntinib

Weersuntinib (LS-007) is an orally bioavailable, small-molecule, irreversible pan-HER tyrosine kinase inhibitor developed by Guangzhou Liushun Biotechnology. It primarily targets the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2). By covalently binding to the ATP-binding site of these receptors, weersuntinib inhibits downstream signaling pathways such as PI3K/Akt and MAPK/ERK, which are frequently overactivated in various cancers. The drug is currently being investigated primarily for the treatment of advanced esophageal squamous cell carcinoma (ESCC), where EGFR overexpression is a common driver of malignancy. Clinical trials in China have focused on patients with advanced solid tumors and specifically those with ESCC who have progressed on standard therapies.